Jump to Main Content
- Yunes Panahi; Reza Yekta; Gholamreza Dehghan; Samaneh Rashtbari; Nematollah Jonaidi Jafari; Ali A. Moosavi-Movahedi
- Biochimie 2019 v.156 pp. 100-108
- aspirin; binding capacity; blood glucose; cardiovascular diseases; catalase; circular dichroism spectroscopy; dialysis; enzyme activity; ligands; liver; patients
- ... Aspirin (ASP) and pioglitazone (PGL) are the most common drugs that are widely used by diabetic patients to control the blood sugar and hinder cardiovascular diseases. The interaction between PGL and ASP is one of the important medical issues to clarify the safety of co-administration of these drugs. In the present study, the effect of co-administered ASP with PGL was investigated on the structure ...
- Francesco Finamore; Jean-Luc Reny; Sarah Malacarne; Pierre Fontana; Jean-Charles Sanchez
- Journal of proteomics 2019 v.192 pp. 258-266
- acetylation; aspirin; blood platelets; cardiovascular diseases; diabetes; glucose; glycation; hyperglycemia; mass spectrometry; patients; prostaglandin synthase; proteins; risk factors; serine
- ... Diabetes is a major risk factor for cardiovascular diseases. Although aspirin is considered a cornerstone of the prevention and treatment of atherothrombotic-related ischemic events, this antiplatelet drug appears to be less effective in patients with poorly controlled diabetes. It has been suggested that the glycation of platelet proteins plays a pivotal role in poor responsiveness to aspirin. Ho ...